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Abstract 
Aims 
Fibromuscular dysplasia (FMD) is a poorly understood disease that predominantly 
affects women during middle-life, with features that include stenosis, aneurysm and 
dissection of medium-large arteries. Recently, plasma proteomics has emerged as an 
important means to understand cardiovascular diseases. Our objectives were: (1) To 
characterize plasma proteins and determine if any exhibit differential abundance in FMD 
subjects versus matched healthy controls; (2) To leverage these protein data to conduct 
systems analyses to provide biologic insights on FMD, and explore if this could be 
developed into a blood-based FMD test. 
 
Methods and Results 
Females with ‘multifocal’ FMD and matched healthy controls underwent clinical 
phenotyping, dermal biopsy and blood draw. Using dual-capture proximity-extension-
assay and nuclear magnetic resonance-spectroscopy, we evaluated plasma levels of 
981 proteins and 31 lipid sub-classes, respectively. In a discovery cohort (Ncases=90, 
Ncontrols=100), we identified 105 proteins and 16 lipid sub-classes (predominantly 
triglycerides and fatty acids) with differential plasma abundance in FMD cases versus 
controls. In an independent cohort (Ncases=23, Ncontrols=28), we successfully validated 37 
plasma proteins and 10 lipid sub-classes with differential abundance. Among these, 
5/37 proteins exhibited genetic control and Bayesian analyses identified 3 of these as 
potential upstream drivers of FMD. In a third cohort (Ncases=506, Ncontrols=876) the 
genetic locus of one of these upstream disease drivers, CD2-associated protein 
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(CD2AP), was independently validated as being associated with risk of having FMD 
(OR=1.36; P=0.0003). Immune-fluorescence staining identified that CD2AP is 
expressed by the endothelium of medium-large arteries. Finally, machine learning 
trained on the discovery cohort was used to develop a test for FMD. When 
independently applied to the validation cohort, the test showed a c-statistic of 0.73 and 
sensitivity of 78.3%.     
 
Conclusions 
FMD exhibits a plasma proteogenomic and lipid signature that includes potential 
causative disease drivers, and which holds promise for developing a blood-based test 
for this disease.  
 
Translational Perspective 
Fibromuscular dysplasia (FMD) is a poorly understood disease with no specific 
therapies, which can cause stenosis, aneurysm and dissection of medium-large 
arteries. At present, FMD is usually diagnosed by imaging studies, and screening for 
this disease can be challenging. We performed a ‘reverse-translational’ clinical study 
leveraging plasma and DNA samples from FMD patients and healthy matched controls 
to better understand this disease. We found that FMD patients exhibit a plasma 
proteogenomic signature that includes promising disease candidates. While further 
development will be required, our proof-of-concept analyses suggest that it may also be 
possible to develop a blood-based test for FMD. 
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Introduction 
Fibromuscular dysplasia (FMD) is a poorly understood disease that may cause 
aneurysm, dissection, tortuosity, stenosis and/or occlusion of medium-large arteries.1-6 
FMD most commonly affects the carotid and renal arteries, although any artery can be 
affected.7 The clinical manifestations reflect the arterial bed involved, with hypertension 
observed most often in patients with renal artery FMD, and headaches or pulsatile 
tinnitus in patients with cervical artery FMD.7 More severe phenotypes may result in 
end-organ ischemia such as transient ischemia attack, stroke, myocardial infarction 
and/or gut ischemia due to associated dissection and/or aneurysm rupture.2,3,8,9  
In the current era, FMD is an angiographic diagnosis with a binary classification 
based on the presence of alternating areas of stenosis and dilation (‘multifocal’ FMD; 
~80% of patients) (Figures 1A and 1B), or, a single area of concentric or tubular 
stenosis (‘focal’ FMD; ~20% of patients).6,7,10 For patients with multifocal FMD, mean 
age at diagnosis is 50-55 yrs and ~90% are female.2,3 In both multifocal and focal FMD, 
there is often a lengthy delay from symptom onset to diagnosis. This is due in part to 
lack of provider knowledge and experience in caring for FMD patients, overlap with 
other common age-related conditions such as essential hypertension, and lack of a 
simple but accurate screening diagnostic test.10   
There is a common misconception that FMD is a rare disease. Various studies 
suggest otherwise. For example, available imaging from over 3000 renal donors 
identified FMD in approximately 4% of cases.11 The prevalence may be even higher in 
symptomatic patients, with 5.8% of patients enrolled in the CORAL (Cardiovascular 
Outcomes in Renal Atherosclerotic Lesions) trial being found to have renal FMD on 
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review of imaging by the angiographic core laboratory.12 This was despite the fact that 
FMD was an exclusion criterion for entry into that study. Among the 499 women in 
CORAL, 8.8% had angiographic evidence of FMD.12 
Prior attempts to identify the cause or etiology of FMD have yielded limited 
results. At present, only a single FMD-associated genetic locus has been identified, 
being the common single nucleotide polymorphism (SNP) rs9349379 in the gene 
encoding Phosphatase And Actin Regulator 1 (PHACTR1).13 Although those findings 
have so far provided limited direct insight on the cause of FMD, they nevertheless shed 
light on the overall genetic basis of this disease – indicating that FMD has a complex 
genetic pattern of inheritance that potentially involves multiple pathobiological 
mechanisms.13  
Circulating plasma proteins are important markers and biologic mediators of 
cardiovascular disease (CVD),14,15 and novel biostatistical methods which take 
advantage of genetic causation can now be applied to high-throughput data such as 
plasma proteomics to better understand disease pathobiology and causation.15-17 
Moreover, as a vascular disease, affected FMD tissues are in direct contact with the 
bloodstream, potentially augmenting any disease-related effects on circulating plasma 
proteins.  
Here, we undertook a high-throughput plasma proteomics study of FMD patients 
as compared to healthy, matched control subjects. We hypothesized that this approach 
might identify specific proteins that are associated with FMD, which in turn, might 
provide insights on the biologic basis of this disease.   
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Methods 
Study Design 
DEFINE-FMD is a systems biology study aiming to DEFINE key disease drivers and 
mediators of FMD. Its forerunner pilot study, the CAUSE study (ClinicalTrials.gov 
Identifier: NCT01808729), enrolled its first ‘run-in’ control subject on October 31st 2012, 
and first FMD patient on February 22nd 2013. As the CAUSE study approached target 
enrolment it was closed (at n = 34 subjects) and we initiated DEFINE-FMD 
(ClinicalTrials.gov Identifier: NCT01967511). Of the original CAUSE study subjects, 4 
FMD cases are included in the current analysis, with the remainder of the FMD cases 
and all controls being from DEFINE-FMD. DEFINE-FMD continues to recruit subjects 
and as of July 2019 over 375 subjects have been enrolled (approximately 50% cases, 
50% controls). Both the CAUSE and DEFINE-FMD studies were approved by the 
institutional review board of the Icahn School of Medicine at Mount Sinai, and all 
subjects gave written informed consent. The investigation conformed to the principles 
outlined in the Declaration of Helsinki.  
All FMD cases in this study, in both the discovery and validation cohorts, were 
seen and assessed in the Mount Sinai Vascular Medicine Clinic. Inclusion criteria for 
entry into DEFINE-FMD include ≥ 18 years of age, being freely willing to participate, and 
fluency in English. FMD cases are required to have a clinical diagnosis of multifocal 
FMD that is confirmed by imaging (computed tomographic angiography, magnetic 
resonance angiography or catheter-based angiography). While DEFINE-FMD was 
recently expanded and is now also enrolling subjects with spontaneous coronary artery 
dissection (SCAD) or cervical artery dissection (CvAD) in the absence of typical 
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multifocal FMD, these subjects with isolated SCAD or CvAD were not included in this 
analysis. However, for this analysis confirmed multifocal FMD cases were permitted to 
have SCAD and/or CvAD. In addition, per our original enrolment criteria through until 
early 2017, only females are included in this analysis. For healthy controls, inclusion 
criteria include no clinical features of FMD, CvAD or SCAD (including no cervical or 
abdominal bruits, an absence of family history of sudden death or aneurysm) and 
absence of any major ongoing systemic disease including any condition requiring 
hospitalization, immune suppression, intravenous or injected medications or that result 
in functional impairment in the performance of activities of daily living. Healthy controls 
are recruited from the general population and are pre-screened by the same clinical 
team and matched to FMD cases according to age, sex, race/ethnicity, and body mass 
index (BMI). Because it would be almost impossible to identify and recruit control 
subjects that are of precisely the same age as every FMD case, healthy control females 
are recruited that broadly match the age and BMI distribution of FMD cases.  
Exclusion criteria (for cases and controls) include: co-morbidities which reduce 
life expectancy to one year; any solid organ or hematological transplantation, or those in 
whom transplantation is considered; active autoimmune disease; illicit drug use; HIV 
positive; prior malignancy. In controls, an additional exclusion criteria is an early-onset 
family history of any form of vascular disease. Healthy controls also undergo screening 
clinical assessment, with specific attention paid to any history or physical examination 
findings suggestive of FMD or other vascular disease, by two clinical experts in FMD 
(JWO, DKD). Notably, 3 patients who initially agreed to be a healthy control were 
diagnosed with FMD after the screening history and physical exam.  
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 If the above entry criteria are met and following informed consent, blood draw 
and skin punch-biopsy (from the medial upper arm) are performed. From the skin 
biopsy, fibroblasts are derived using explant culture outgrowth techniques (fibroblast 
data are not presented here). At the blood draw, 20 ml of blood are collected: 10 ml is 
collected into EDTA tubes and is reserved for DNA extraction, while 10 ml is collected in 
EDTA-anticoagulated (plasma) and non-anticoagulated (serum) tubes (5ml each) and 
reserved for plasma/serum preparation. Samples are transported at room temperature 
for processing within 15 minutes. To obtain plasma, EDTA-anticoagulated blood is 
centrifuged at 2000 g for 10 minutes. Blood for preparation of serum is also centrifuged 
at 2000 g for 10 minutes. Plasma and serum are then aliquoted and immediately frozen 
at -80oC pending batched analysis (only plasma was processed for this study). DNA is 
isolated from whole blood using the Puregene Blood Core kit B (cat# 158467, Qiagen, 
Germantown, MD, USA). DNA was aliquoted and frozen at -80oC. 
 
Subjects 
In February 2017 we identified 90 FMD cases and 100 matched controls from the 
CAUSE (4 cases) and DEFINE datasets (86 cases and all controls) for the discovery 
phase of this analysis. For this analysis we imposed the additional inclusion/exclusion 
criteria that controls cannot be related to FMD cases, that the age ranges of cases and 
controls should be the same, that only persons of self-reported Caucasian race/ethnicity 
be included in this analysis (to reduce background genetic and proteomic variation), and 
that any subject taking clopidogrel, ticagrelor or prasugrel also be excluded. The latter 
criterion was imposed because these medications are typically used in unstable patients 
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or those with recent clinical events, in which acute-phase inflammatory proteins may 
have confounded any FMD-specific protein signature. 
 For the validation cohort, the same criteria were applied and in March-April 2018 
an additional 23 FMD cases and 28 matched healthy controls were identified from the 
ongoing subjects recruited to the DEFINE-FMD study. 
Importantly, while the discovery cohort was enrolled from October 2012 until 
February 2017, and the validation cohort was enrolled separately from March 2017 to 
April 2018, throughout the entire study and for both cohorts we enrolled FMD cases and 
controls concurrently, at the same site and by the same investigative team, and with all 
samples handled identically. 
 
Power calculations and sample size estimates  
For the initial discovery phase of this study, power calculations and samples size 
estimates were not possible, because plasma proteins had not been studied in FMD 
patients. However, our discovery cohort sample size was chosen to be similar to other 
recent successful studies of this nature.17     
 For the validation phase of the study, analyses and validation sample sizes were 
determined in advance. We first evaluated the power of a validation proteomics study 
based on data collected from the discovery cohort. Specifically, we considered a one-
sided t-test type-1 error alpha = 0.05, with absolute effect sizes and variability estimated 
from the discovery cohort on the 105 FMD discovery signature proteins. Through a 
Monte-Carlo procedure, for validation sample sizes of n = 20, 25 and 30 per group (i.e., 
40, 50 and 60 subjects in total), we estimated a median number of replicated proteins of 
CVR‐2019‐0697 
 
11 
 
43, 51 and 57, respectively, out of the 105 obtained from the discovery cohort. Based 
on these estimates, our final validation cohort comprised 23 FMD cases and 28 
matched healthy controls (51 subjects in total).  
 
Olink protein array 
For protein analysis plasma samples were shipped on dry ice and processed by Olink 
(Watertown, MA, USA). Analyses were performed using a high-throughput technique 
using all 11 available Olink panels to measure a total of 981 unique human proteins 
using 1012 probes. The Olink platform uses proximity extension assay (PEA) 
technology, where oligonucleotide-labeled antibody probe pairs are allowed to bind to 
their respective target present in the sample.18-20 The PEA technique has the advantage 
that only correctly matched antibody pairs give rise to a signal, providing high specificity. 
The discovery and validation cohorts were processed as two separate batches (April-
May 2017 and April 2018, respectively). Data were received as normalized protein 
expression (NPX) values; Olink Proteomics’ arbitrary unit on log2 scale. Values below 
Limit Of Detection (LOD) were replaced with “Not a number (NaN)”. We transformed 
those measures into ‘Signal-To-Noise Log-Ratio’ as follows: SNLR[i,j] = NPX[i,j] – 
LOD[j], where ‘i' is the sample indicator, and ‘j’ is the probe indicator. No probes or 
samples were excluded from the analysis after quality control. 
 
Nightingale lipid array data 
Plasma was shipped on dry ice to Nightingale Health Ltd. (Kuopio, Finland) for 
processing on their high-throughput nuclear magnetic resonance spectroscopy (NMR) 
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metabolomics platform. The platform applies a single experimental setup, which allows 
for the simultaneous quantification of routine lipids, lipoprotein sub-classes and 
individual lipids transported by these particles. Details of this platform have been 
published previously,21,22 and it has been widely applied in genetic and cardiovascular 
epidemiological studies.23-28 Due to redundancy in markers and in order to reduce 
multiple comparison testing, we limited our analysis to 31 primary lipid parameters 
classified under the categories of apolipoproteins, cholesterol, fatty acids and 
saturation, glycerides and phospholipids, and lipoprotein particle sizes. Notably, while in 
total there are 40 parameters classified into these categories by Nightingale, we 
removed 9 parameters that are secondary ratios derived from the primary data. 
 
Machine learning test algorithm for FMD 
We built models incorporating demographic variables plus plasma protein levels only, 
and demographic variables plus both plasma protein and lipid levels, to predict FMD 
case/control status. Firstly, the R impute package29 was applied to fill any missing data 
points in the protein and lipid datasets. In detail, the R impute package employs a 
nearest neighbor algorithm. For each protein or lipid with missing values, the program 
found the k-nearest neighbors using a Euclidean metric, where k was set to 10 (the 
software’s default value). Each candidate neighbor might contribute some of the missing 
coordinates in computing the Euclidean distance; in this case, the program computes 
the distance using all the non-missing coordinates. Having found the k-nearest 
neighbors for a protein or lipid, the program imputed the missing value using the 
average of the neighbors. For the discovery cohort plasma protein dataset there were 
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192280 data points (190 subjects x 1012 olink probes), of which 4416 were missing and 
were imputed (2.3%); for the discovery cohort plasma lipid dataset there were 5890 
data points (190 subjects x 31 parameters) of which 210 were missing and were 
imputed (3.6%). For the replication cohort plasma protein dataset there were 51612 
data points (51 subjects x 1012 olink probes), of which 1670 were missing and were 
imputed (3.2%); for the replication cohort plasma lipid dataset there were 1581 data 
points (51 subjects x 31 parameters) of which 60 were missing and were imputed 
(3.8%). 
We then followed the classic machine learning work-flow and in an initial “training 
phase” the prediction models were constructed using only the discovery cohort protein 
and lipid datasets (n = 190 subjects). Since we had a large number of potential 
predictors (i.e., protein and lipid traits) and certain predictors were inter-correlated 
(Figure 4), a feature selection step was applied to select a set of predictors providing 
non-redundant information. In detail, we applied an elastic net method which evaluates 
all the protein and lipid traits simultaneously, and set the regression coefficients of both 
the non-informative and redundant predictors as zero.30,31 Next, we selected the 
predictors of non-zero elastic net regression coefficients, which form a set of non-
redundant predictors for FMD.30,31 To then formally construct the prediction models we 
applied a random forest method, specifically because it is an accurate ensemble 
classifier that consists of many decision trees and outputs, which can also effectively 
handle a large number of input variables.32 We applied the “randomForest” package in 
R, which decorrelates the multiple trees generated though different bootstrapped 
procedures from the training data. Subsequently, “randomForest” also reduces the 
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variance in the trees by averaging them, which results in the final prediction models. 
Having finalized the predictive models and completed the “training phase” using the 
discovery cohort datasets, we then moved into an independent “testing phase.” In the 
testing phase, the random forest models were independently applied and evaluated in 
the validation cohort datasets (n=51), and we quantified prediction accuracy, receiver 
operating characteristic (ROC) curve and area under the ROC curve (c-statistic). The 
validation cohort datasets or results were not used, in any way, to adjust or tune the 
predictive models.  
 
Additional study details and methods 
Further study details, scientific methods and statistical methods are provided in the 
Supplementary Appendix.  
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Results 
Patient demographics 
A total of 90 multifocal FMD patients and 100 healthy, age- and sex-matched controls 
were included in the discovery cohort of this study. All cases and controls were female 
and of self-reported Caucasian ethnicity (Table 1). 
 
A plasma protein signature of FMD 
The proteomics platform used for this study (proximity-extension-assay [PEA]; Olink) 
allowed the evaluation of plasma levels of 981 proteins. After statistical correction for 
age and body mass index (BMI), at 10% false discovery rate (FDR), we identified 105 
proteins (104 distinct gene symbols) with differential abundance in FMD cases 
compared to controls (Figure 1C, Table S1). Most proteins showed moderate effect 
sizes with log2 fold changes (log2-FC) less than 0.5, with the most notable exceptions 
being fibroblast growth factor 19 (FGF19; log2-FC = -0.86) and the peptide hormone 
glucagon (GCG; log2-FC = -0.71) (Figure 1C).  
 To characterize this FMD plasma protein signature, we ran a Gene Set 
Enrichment Analysis (GSEA) against all collections of the MSigDB database. At 10% 
FDR, we found 4 enriched Gene Sets (GS) in the curated collection, 8 in the GO 
biological processes collection, 23 in the GO cellular components collection, and 32 in 
the GO molecular function collection (Table S2). Of the 8 most strongly represented 
terms (all < 1% FDR), 4/8 were involved with chemokine and cytokine signaling. 
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FMD plasma protein signature is independent of medication use 
Overall, FMD cases and healthy controls were well matched (Table 1). However, as 
might be expected, FMD cases had greater use of aspirin, ACE/ARBs (angiotensin 
converting enzyme inhibitors and angiotensin receptor blockers, respectively), beta 
blockers and statins (Table 1). Therefore, a number of analyses were performed to 
determine if medication use was responsible for protein changes that were part of the 
FMD protein signature. First, the impact of these four medication classes on plasma 
protein levels was assessed by evaluating their effect within FMD patients only. There 
were no significant differences in protein levels with either aspirin or beta blocker use 
among FMD patients. ACE/ARB use was only associated with increased plasma renin 
levels (log2-FC = 0.93), while statin use was only associated with increased levels of 
PCOLCE (Procollagen C-endopeptidase enhancer 1; log2-FC = 0.93). Neither renin nor 
PCOLCE were among the 105 signature proteins associated with FMD. Second, we 
compared the impact of differing medications and FMD disease status on plasma 
protein levels, and found that the pattern of association of the signature proteins with 
FMD status was not mirrored in the medication profiles (Figure 2, Table S3). Third, we 
built an alternative FMD regression model where we sequentially excluded cases and 
controls according to use of differing medication classes. These alternate FMD protein 
lists consistently overlapped with our full FMD protein signature obtained by including all 
subjects, with odds ratios (OR) of overlap with the full signature of between 4.4 and 
10.7, and Fisher test P values < 1x10-31 (Table S4). These three, concordant analyses 
indicate that medication use is unlikely to be a major confounding factor in the FMD 
plasma protein signature.  
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A lipid signature of FMD 
We noted that the FMD protein signature contained many proteins that regulate plasma 
lipid levels (Table S5). Therefore, we hypothesized that in addition to plasma proteins, 
FMD may also be associated with alterations in plasma lipid levels. Accordingly, we 
elected to profile plasma lipid and lipoprotein levels by NMR. For the data analysis, 
given the known associations with statin use and lipid levels, to explore the possible 
relationship between FMD and lipid levels we constructed a fully adjusted model that 
included age, BMI, statin use and the use of non-statin lipid lowering agents. In this fully 
adjusted analysis, we observed differential abundance of 16 of a total of 31 lipid-related 
parameters (Figure 1D, Table S6). Notably, FMD cases had reduced levels of several 
lipid moieties; most notably of triglyceride- and fatty acid-related lipid sub-classes. Of 
the top 3 most significantly reduced lipid fractions we observed reduced LDL-
triglycerides (triglycerides in LDL), reduced HDL-triglycerides (triglycerides in HDL) and 
reduced saturated fatty acids. We observed only a single lipid parameter that was 
increased in FMD cases versus controls, which was the degree of unsaturation of all 
fatty acids (Figure 1D, Table S6). Alternate statistical approaches that included using a 
more flexible model for age as a covariate did not alter these findings (Figure S1). 
Furthermore, to confirm the general validity of our lipid datasets we sought and were 
able to replicate known lipid-associated gene loci (Figure S2). Thus, in addition to a 
plasma protein signature, FMD is associated with an altered lipid profile, most notably 
with reduced levels of triglycerides and saturated fatty acids.   
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Independent validation of a plasma protein and lipid signature for FMD 
We sought to validate the FMD plasma protein and lipid signature using an independent 
validation cohort, which based on sample size and power estimates (see Methods) 
comprised 23 FMD patients and 28 matched controls (total subjects = 51). Subject 
inclusion/exclusion criteria, subject recruitment and sample processing were identical to 
the discovery cohort. Cases and controls in the validation cohort were well matched and 
the disease-specific features of the FMD cases were similar to the discovery cohort 
(Table S7). The criteria for validation were proteins which showed association with FMD 
in the validation cohort in the same direction as the discovery cohort, with a one-sided, 
nominal P value < 0.05. We found that 37 of the original 105 differentially abundant 
proteins and 10 of the original 16 differentially abundant lipids were validated in this 
independent cohort (Figures 1C and 1D – proteins with blue halo).  
All proteins and lipids were analyzed in a pooled dataset composed of all 
subjects from both the discovery and validation cohorts (113 FMD cases, 128 matched 
healthy controls). The top two protein candidates from the discovery analysis, FGF19 
and the peptide hormone glucagon, were both validated and in the pooled analysis 
these remained as the top two differentially abundant proteins. Validated proteins and 
lipids are shown in Figure 3, with complete results for all markers presented in Table S1 
(proteins) and Table S6 (lipids). 
To gain insights on the potential mechanisms whereby upstream proteins may be 
associated with or regulate lipid levels in FMD patients, this pooled dataset was used to 
perform a cross-correlation of the 37 validated FMD signature proteins with the 10 
validated plasma lipids. This revealed that levels of FGF19, glucagon, PRSS8 and 
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SNAP29 were each associated with the levels of several differing lipid sub-classes, 
while levels of proteins CA13, GRAP2, SEZ6L were each associated with the levels of 
one or two lipid sub-classes (Figure 4). Adding validity to these findings, we note that 
the many of these protein-lipid associations (Figure 4) have previously been described 
(Table S5).  
This pooled dataset was also leveraged to determine if there were any 
associations between plasma protein or lipid levels with FMD disease features or 
severity. This exploratory analysis suggested that several FMD disease features and 
markers of severity may be associated with specific proteins and lipids, although none 
of these associations reached statistical significance (Tables S8 and S9).   
 
A proof-of-concept plasma protein test for FMD 
Given the diagnostic challenges posed by FMD,1,6,10 machine learning was performed to 
study the possibility that a specific plasma protein/lipid signature might have efficacy as 
a diagnostic test to predict the clinical likelihood of having FMD. We exclusively trained 
and developed FMD predictive models using the discovery cohort datasets, and used 
the validation cohort as fully independent datasets to evaluate prediction performance. 
An initial model incorporating 34 proteins (selected by elastic net, see Methods) was 
generated using the discovery cohort datasets and independently evaluated on the 
validation cohort yielding a c-statistic of 0.61 (Figure 5). Of these 34 proteins, 6 were 
among the 37 plasma proteins that we validated as being associated with FMD (Figure 
3). Next, we explored using the lipid data in conjunction with the protein and 
demographic data. In a model incorporating the same 34 proteins and all 31 lipid 
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parameters, a random forest prediction model for FMD was developed and evaluated 
on the independent validation cohort, yielding a c-statistic of 0.73, with a sensitivity of 
78.3%, specificity 64.3%, positive predictive value 64.3%, and negative predictive value 
78.3% (Figure 5).  
 
Identification of novel risk genes for FMD 
To seek potential novel genes that are associated with the risk of having FMD, we 
performed protein-QTL (pQTL) mapping on confirmed Caucasian FMD patients and 
healthy control subjects in the discovery cohort. In brief, a pQTL is a DNA variant (SNP) 
that is associated with the levels of a specific plasma protein, with cis pQTLs being local 
to the protein-coding gene, and trans pQTLs being at a distance. At 10% FDR, we 
found 193 cis and 34 trans pQTLs, for a total of 219 distinct probes. Of the proteins 
associated with these 219 pQTLs, 5 were among the 37 validated proteins that showed 
differential abundance between FMD cases and healthy controls (Figure 3), being 
CD2AP, PODXL2, TACC3, INPPL1 and CRTAC1. Complete association statistics 
between all tested variants and all array probes are reported in Table S10. 
We conducted a Bayesian network analysis to better understand the relationship 
between these 5 FMD signature proteins with an associated pQTL, the genotype of the 
distinct variants which were found to control these proteins, and FMD disease status 
(Table 2). Of the 5 analyzed proteins, INPPL1 was classified as downstream of FMD 
(i.e. its regulation is a consequence and not a cause of FMD), CRTAC1 was classified 
as independent (i.e. a common latent factor simultaneously influences the protein level 
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and disease status), while CD2AP, PODXL2 and TACC3 were classified as upstream of 
the disease (i.e. they may be causally related to FMD).  
	
CD2AP is a novel gene that is associated with FMD 
We leveraged an independent FMD genetic association study (with 506 FMD cases and 
876 controls)13 and queried the associations of the genes that encode the five FMD 
signature proteins with an associated pQTL (CD2AP, PODXL2, TACC3, INPPL1, 
CRTAC1). Consistent with the Bayesian analysis which showed they are either 
downstream or independent of FMD, there were no associations found for INPPL1 or 
CRTAC1. There were also no associations found for PODXL2 and TACC3. However, 
we identified a significant association with several loci that were in close linkage 
disequilibrium in the region upstream of CD2AP, with most of these having a P value of 
~ 0.001, and with the most strongly associated being rs9296551 (OR = 1.36, P = 
0.0003) (Figure 6A). 
 Having validated a genetic association, we sought to explore potential 
mechanism(s) whereby CD2AP may be causal for FMD. Although CD2AP is known to 
be expressed by capillary endothelial cells in the cerebral microcirculation and lung,33,34 
to the best of our knowledge its expression has not been studied in medium-large 
arteries (as are affected by FMD). We therefore performed immune-fluorescence 
staining for CD2AP in the human aorta, renal artery and internal mammary artery. 
These experiments revealed consistent and robust expression of CD2AP by endothelial 
cells in these vessels (Figures 6B - 6D), suggesting the possibility that changes in 
CD2AP may result in perturbation of endothelial cell function.   
CVR‐2019‐0697 
 
22 
 
Relationship between FMD-associated SNP rs9349379 and plasma proteins/lipids 
The SNP rs9349379 is associated with FMD,13 and a prior study suggested that this 
SNP may contribute to vascular disease pathology by modulating plasma endothelin-1 
levels.13,35 Therefore, we queried potential associations with this SNP. In fully adjusted 
analyses, there were no plasma protein (Table S11, Figures S3 and S4) or lipid 
parameters (Table S12) associated with genotype at rs9349379, suggesting that this 
SNP is unlikely to exert any disease-relevant effects for FMD via modulation of plasma 
protein or lipid levels.  
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Discussion 
Despite it being 60 years since the first FMD pathologic classification system was 
reported,36,37 remarkably little is known about the etiology or pathologic mechanisms of 
this disease. Here, we present the first plasma proteomics and lipidomics analysis for 
FMD. Important novel findings from this study include: 1) The identification and 
validation of 37 proteins that comprise a unique FMD disease signature; 2) The 
identification and validation of an additional 10 plasma lipid sub-fractions that comprise 
an FMD lipid signature; 3) Among the 37 validated signature proteins we found that 5 
have an associated pQTL(s); 4) By Bayesian analysis, 3 of these 5 proteins with an 
associated pQTL(s) appear as upstream in the FMD disease process and accordingly, 1 
of the genes associated with an upstream pQTL (CD2AP) was validated as being 
associated with FMD (P = 0.0003). It was further shown that CD2AP is expressed by 
endothelial cells in medium-large sized human arteries – the same vessels that are 
affected in FMD; 5) As proof-of-concept, a pilot FMD test was generated by machine 
learning on the plasma protein and lipid signatures of the discovery cohort, that when 
independently applied to the validation cohort had a c-statistic of 0.73 and sensitivity of 
78.3% for diagnosing FMD. 
 The most important finding arising from this study is the identification of a 
signature of plasma protein and lipid changes in patients with FMD (Figure 3). It 
remains to be determined which of these changes are causal for FMD, however, the 
most promising candidate to emerge from this study was CD2AP. In addition to showing 
increased abundance in FMD cases versus controls in the discovery and validation 
cohorts, a link between CD2AP and FMD is suggested by the following observations: 1) 
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CD2AP was 1 of only 5 signature proteins to exhibit genetic regulation (i.e. pQTLs); 2) 
Our Bayesian analysis suggests that CD2AP is an upstream driver of the FMD disease 
process; 3) We validated an association between FMD and several genetic variants in 
the vicinity of CD2AP (P = 0.0003); 4) CD2AP is strongly expressed in the endothelium 
of medium-large human arteries (as are involved in FMD) (Figure 6); 5) Based on prior 
literature,33,38-41 CD2AP is a strong candidate for a functional role in FMD. Specifically, 
while CD2AP may also be involved in other processes,42,43 polymorphism(s) in CD2AP 
are associated with Alzheimer’s disease.38-40 Murine studies have suggested that the 
mechanism of involvement in Alzheimer’s disease may be via a CD2AP-mediated 
perturbation in inter-cellular adhesion41 and endothelial function,33 leading to 
compromised vascular integrity and blood-brain barrier function.33 As a clinical correlate, 
one of the major FMD sub-phenotypes is arterial dissection (Table 1), where 
compromised vascular integrity is likely to be an underlying precipitant. Thus, there are 
reasonable grounds to believe that CD2AP may play a causal role in the pathogenesis 
of FMD.  
 Apart from CD2AP, other FMD signature proteins may also be involved in FMD 
disease causation. For example, PODXL2 (also known as endoglycan – a member of 
the CD34 family of proteins) is another of the three proteins identified as being 
potentially causative of FMD in the Bayesian analysis (Table 2). Although understudied, 
PODXL2 is expressed by the endothelium and acts as a ligand for vascular selectins, 
whereby it mediates the interaction of leukocytes with vascular surfaces through 
interactions with E-, P- and L-selectins.44 Conceivably, perturbation of leukocyte-
endothelial interactions in medium-large sized arteries could alter local vascular immune 
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homeostasis, which over the longer-term might lead to unfavorable changes that 
culminate in FMD.  
The favorable alterations in triglyceride and fatty acid levels in FMD patients were 
unexpected (Figures 1D and 3), but not without precedent. Interestingly, a prior study in 
patients with cervical artery dissection, a disease that is related to and sometimes 
overlaps with FMD,2 found that subjects with cervical artery dissection have a lower 
prevalence of hypercholesterolemia compared to controls.45 As a possible explanation 
for the generally reduced lipid levels in FMD subjects, it is possible that FMD-associated 
changes in endothelial cells might affect endothelial lipase,46,47 or that other 
determinants of lipid handling by the vessel wall are perturbed in FMD. However, it is 
also possible that altered lipid levels are merely secondary association of FMD, or even, 
that altered lipid levels are upstream and causal for FMD. 
 At present, FMD is usually diagnosed by imaging studies. While alternatives 
exist, the preferred imaging modality for diagnosing FMD is computed tomographic 
angiography (CTA),1,9,48 with current data supporting one-time ‘head-to-pelvis’ CTA in all 
FMD patients.2,6,48,49 Screening for FMD is challenging, and asymptomatic FMD patients 
or those with non-specific symptoms (e.g. pulsatile tinnitus) may remain undiagnosed 
for many years or until they suffer a major event.1,7,10 As a possible solution, our proof-
of-concept diagnostic algorithm suggests that it may be possible to develop a blood-
based test for FMD. A reliable blood-based FMD test would likely have a major impact 
on the management of this disease, including aiding diagnosis, screening family 
members, facilitating family counseling, tailoring of clinical care and other applications. 
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With respect to study limitations, protein levels were not separately measured by 
individual enzyme-linked immunosorbent assay (ELISA), except endothelin 1 (Figure 
S3). Instead, to multiplex protein measurements we took advantage of PEA technology. 
Accuracy is the hallmark of PEA technology,18-20 where dual binding of antibodies must 
occur in close proximity to detect and measure protein abundance. Similarly, lipid 
parameters were measured in this study using another advanced technique - NMR 
spectroscopy. Recently, numerous studies have attested to the accuracy of both PEA18-
20 and NMR,21-28 and rather than being a limitation, we believe that our reliance on these 
platforms is a potential strength of this study. Other considerations include a relatively 
small sample size, and the need for further mechanistic studies to understand the role 
of the signature FMD proteins and lipids. While promising, the proof-of-concept 
diagnostic FMD test also requires further development and evaluation in larger cohorts.     
In conclusion, patients with multifocal FMD exhibit a plasma proteogenomic 
signature that includes promising candidates such as CD2AP, which merit future 
investigation as potential novel disease drivers. In addition, patients with FMD exhibit 
favorable alterations in their plasma lipid profile, most notably reduced triglyceride and 
fatty acid levels. While further development and evaluation will be required, our proof-of-
concept analyses suggest that it may be possible to develop a blood-based test for 
FMD. 
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Figure Legends 
Figure 1. Typical multifocal FMD and differential protein levels between FMD 
cases and matched healthy controls in the discovery cohort dataset. (A) Catheter-
based angiographic image representative of the typical appearance of multifocal FMD 
affecting the carotid artery. (B) Typical catheter-based angiographic appearance of 
multifocal FMD affecting the renal artery, with so called ‘string-of-beads’ appearance. 
(C) Volcano plot of the differential protein level analysis comparing FMD patients to 
healthy controls; log2-fold change (log2-FC) on the horizontal axis, -log10(P value) on 
the vertical axis; the horizontal blue line marks the 10% FDR significance threshold. 
Selected proteins with large effect size or of further interest are labeled. Proteins that 
were subsequently validated (in the separate validation cohort) are represented with a 
blue halo. (D) Volcano plot of the differential lipid and lipoprotein level analysis in a fully-
adjusted model comparing FMD patients to healthy controls (co-variates were age, BMI, 
statin use and non-statin lipid lowering medication use); log2-FC on the horizontal axis, 
-log10(P value) on the vertical axis; the horizontal blue line marks the 10% FDR 
significance threshold. Selected lipid and lipoprotein species with largest effect size are 
labeled. Lipids that were subsequently validated (in the separate validation cohort) are 
represented with a blue halo. ApoB, Apolipoprotein B; FreeC, free cholesterol; HDL-TG, 
triglycerides in HDL; LA, 18:2 linoleic acid; LDL-TG, triglycerides in LDL; MUFA, 
monounsaturated fatty acids 16:1, 18:1; PC, phosphatidylcholine and other cholines; 
Remnant-C, remnant cholesterol (non-HDL, non-LDL -cholesterol); Serum-TG, serum 
total triglycerides; SFA, saturated fatty acids; TotFA, total fatty acids; UnSat, estimated 
degree of unsaturation of all fatty acids (the numeric value is an estimate of the average 
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number of double bonds in the fatty acid chains); VLDL-C, total cholesterol in VLDL; 
VLDL-TG, triglycerides in VLDL. 
 
Figure 2. The FMD protein signature is not due to medication use. FMD signature 
protein heatmap with the 105 signature FMD proteins from the discovery cohort 
presented in rows, and with z-scores of association with FMD shown in the first column, 
and different key medication classes in the other columns. FMD status (first column) 
was determined using all subjects, while medication use (other columns) was 
determined in FMD cases only. As expected, FMD disease status was strongly 
associated with each of these FMD signature proteins, while there was no association 
of these signature proteins with the use of differing classes of medications. Z-scores of 
protein associations with FMD disease status (all subjects) and differing classes of 
medication use (estimated within FMD patients only) corresponding to this Figure are 
presented in Table S3. 
 
Figure 3. FMD protein and lipid signature. Forest plot of association between 
validated FMD proteins and lipids, and FMD status, in 3 datasets: discovery cohort 
(gray lines), validation cohort (gold lines) and pooled cohort (blue lines). Estimated log2 
fold changes on the horizontal axis, protein and lipid labels on the vertical axis. Point 
estimates and 95% confidence intervals are further reported on the right. 
 
Figure 4. Cross-correlations between validated FMD signature proteins and lipids. 
(A) Heatmap of Pearson cross-correlations: proteins in rows, lipids in columns. (B) 
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Corresponding table of cross-correlations below the 10% FDR cutoff. NGID, Nightingale 
identification code. 
 
Figure 5. A diagnostic test algorithm for FMD. Machine learning was used to 
generate diagnostic algorithms for predicting that a subject has FMD. Algorithms were 
exclusively generated using the discovery cohort datasets. Data shown in this Figure 
represent the independent application of these algorithms to the validation cohort 
datasets. (A) Receiver operating characteristic (ROC) curve for a diagnostic algorithm 
for predicting FMD based only on plasma proteins (red), and also based on both the 
protein and lipid data (green). (B) Performance characteristics of the diagnostic test for 
FMD based only on protein data (as related to red line in A), when independently 
applied to the validation dataset. A total of 34 proteins were included in this model. (C) 
Performance characteristics of the diagnostic test for FMD based on the protein and 
lipid data (as related to green line in A), when independently applied to the validation 
dataset. A total of 34 proteins and all 31 lipid parameters were included in this model. 
Age and other demographic data did not enter into these models. 
 
Figure 6. CD2AP is associated with FMD and is expressed by endothelial cells. (A) 
Locus zoom plot showing the peak of association with FMD risk, upstream of the gene 
encoding CD2AP. (B-D) Immune-fluorescence staining for CD2AP was performed on 
adult human non-FMD samples from (B) renal artery, (C) internal mammary artery and 
(D) aorta. Endothelial cells were specifically identified by staining for CD31 (green), 
while CD2AP is shown in red. Nuclei were stained with DAPI (blue). Scale bar 
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represents 25 μm. Inset panels on the right, representing an enlarged view of the area 
in the respective dashed squares, show endothelial cells at higher magnification. M, 
tunica media; L, lumen. All images are representative, and consistent results were 
obtained from staining of the aorta, internal mammary artery and renal artery from at 
least 3 different subjects for each sample type. 
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Tables 
Table 1. Discovery cohort demographic summary statistics. 
 
  FMD patients (n=90) healthy controls (n=100) 
 variable summary* n summary* n
Clinical     
 Sex: female 90 (100.00%) 90 100 (100.00%) 100
 Age at FMD diagnosis 54 [24 – 73] -
 Age at study enrollment 57 [32 – 74] 90 50 [34.0 – 74.0] 100
 Height (in) 64.0 [58.0 – 71.0] 90 65.0 [59.0 – 73.0] 100
 Weight (lbs) 136.5 [103.0 – 208.0] 90 141.0 [100.0 - 240.0] 100
 BMI 23.1 [18.3 – 33.6] 90 23.8 [16.6 – 38.7] 100
 DM 2 (2.22%) 90 1 (1.00%) 100
 HTN 54 (60.00%) 90 4 (4.00%) 100
 Ever smoker  18 (20.00%) 90 18 (18.00%) 100
Medication use   
 ACE/ARB 31 (34.44%) 90 2 (2.00%) 100
 Aspirin 72 (80.00%) 90 5 (5.00%) 100
 Anticoagulation 5 (5.56%) 90 0 (0.00%) 100
 Beta blocker 22 (24.44%) 90 4 (4.00%) 100
 Current hormone therapy 5 (5.56%) 90 10 (10.00%) 100
 Statin 33 (36.67%) 90 6 (6.00%) 100
 Non-statin lipid lowering 
Thyroid replacement 
13 (14.4%) 
18 (20.00%)
90 
90
1 (1.00%) 
12 (12.00%)
100 
100
FMD vascular features   
 Aneurysm† 30 (33.33%) 90 - 
 Dissection† 34 (37.78%) 90 - 
Prior TIA/CVA 
FMD arterial disease location 
13 (14.61%) 89  - 
 Cervical (Carotid/Vertebral) 70 (77.78%) 90  - 
 Coronary# 3 (3.33%) 90  - 
 Iliac 6 (6.67%) 90  - 
 Intracranial# 12 (13.33%) 90  - 
 Mesenteric 17 (18.89%) 90  - 
 Renal 66 (73.33%) 90  - 
FMD arterial bed involvement    
 Total number of arterial 
beds involved 
2.0 [1.0 – 4.0] 90  - 
Except where stated, all data are as at the time of study enrolment.  
* Total number of subjects with the described characteristic for yes/no features 
(percentage in parenthesis); median and min-max range for continuous features. 
† Aneurysm or dissection are considered a manifestation of FMD only if multifocal (or 
focal) findings are observed in a separate vascular bed.  
# Due to the specific features of FMD in these vascular beds, ‘coronary FMD’ implies a 
CVR‐2019‐0697 
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coronary artery dissection, while ‘intracranial FMD’ implies an intracranial aneurysm.  
ACE = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; 
DM = diabetes; HTN = hypertension; statin = HMG-CoA reductase inhibitor; TIA = 
transient ischemic attack; CVA = cerebrovascular accident 
 
 
 
 
 
 
Table 2. Bayesian Network Analysis Results 
Bayesian network classification of the 5 validated FMD signature proteins which were 
found to be genetically regulated. In the 4th column we further report our estimated 
log2-fold change (log2-FC) in protein levels between FMD cases and healthy controls. 
By ‘classification’ according to this Bayesian analysis, ‘downstream’ implies that 
regulation of this protein is a consequence and not a cause of FMD, ‘independent’ 
implies a common latent factor simultaneously influences the protein level and disease 
status, while ‘upstream’ suggests that the protein may potentially be causal for FMD. 
 
OlinkID Gene symbol Classification FMD log2(FC) 
OID01056 INPPL1 downstream 0.33 
OID01304 CRTAC1 independent -0.29 
OID01133 CD2AP upstream 0.43 
OID01389 PODXL2 upstream 0.14 
OID01399 TACC3 upstream 0.25 
 
C D 
B A 



B 
A 
C 
FMD test based on 
protein data only 
True Disease Status 
FMD Control 
Predicted 
Disease 
Status 
FMD 16 17 
Control 7 11 
Sensitivity 69.6% 
Specificity 39.3% 
PPV 48.5% 
NPV 61.1% 
FMD test based on 
protein and lipid 
data 
True Disease Status 
FMD Control 
Predicted 
Disease 
Status 
FMD 18 10 
Control 5 18 
Sensitivity 78.3% 
Specificity 64.3% 
PPV 64.3% 
NPV 78.3% 
Plasma proteins (c-statistic: 0.61) 
Plasma proteins + lipids (c-statistic: 0.73) 
A 
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Supplemental Methods 
 
Measurement of plasma endothelin-1 levels 
EDN1 Quantikine Enzyme-linked Immunosorbent Assay (ELISA) kits were purchased 
from R&D Systems (cat. DET100, R&D Systems, Minneapolis, MN) and plasma was 
processed according to the manufacturer’s instructions. Absorbance at 450 nm was 
measured on a plate reader (Infinite 200 Pro, Tecan, Männedorf, Switzerland) using 570 
nm as a reference wavelength. Results were calculated using a four-parameter logistic 
fit. 
 
Genotyping data 
Samples were processed in two batches of 112 and 128 samples (240 in total), 
respectively, which included additional CAUSE and DEFINE study subjects that were 
not included in this analysis. All samples showed a call rate > 99%, and were thus 
retained. No genetically identical pairs were found, no outliers were identified in a 
Principal Components Analysis (run using eigenstrat1), and all samples were correctly 
predicted as females. Further inspection of the samples’ heterozygosity also revealed 
no outliers. Genotyping array probes were filtered according to call rate (> 95%) and 
Hardy-Weinberg equilibrium test P value (> 1x10-6). In the first batch, 961,962 probes 
passed the filters, and 2,231 failed; in the second batch 958,840 probes passed the 
filters, and 2,079 failed. Data from the two batches were then merged along 949,070 
shared variants. 
In order to identify subject ethnicity, we projected the assayed genotype data on 
the first two genetic principal components from the hapmap panel. Of the 240 subjects 
with genotype data we visually identified 214 subjects of Caucasian ancestry, and 26 of 
other ancestry. Of the 90 FMD cases and 100 controls in the discovery cohort 170 were 
identified as Caucasian while, despite the fact that all were of self-reported Caucasian 
ancestry, 20 were found to have at least partial non-Caucasian ancestry (9 cases and 
11 controls). Genotyping data was imputed using the HRC (haplotype research 
consortium, http://www.haplotype-reference-consortium.org/) reference and the 
Michigan Imputation Server, using the MACH/minimac imputation pipeline. We 
successfully imputed 17,378,389 variants. 
 
Differential protein level analysis 
Differential protein level analysis comparing FMD patients to healthy controls was 
performed using a linear regression for each protein array probe, using the probe 
intensity as the outcome, a 0/1 indicator status for FMD, and the following additional 
covariates: age, BMI and cohort ID (when relevant). Significance of the association was 
quantified via t test on the FMD coefficient. False discovery rate (FDR) was quantified 
6 
using the Benjamini-Hochberg procedure. Multiple probes annotated with the same 
gene symbol were handled as independent markers. 
Association of protein levels with other clinical features was estimated within 
FMD patients separately for each feature, using a linear regression having the probe 
intensity as the outcome, and the clinical feature of interest as a regressor. Age, BMI 
and cohort ID (when relevant) were included as covariates. Associations with both FMD 
and other clinical features were estimated within the discovery cohort only, validation 
cohort only, and in the pooled dataset. 
 
Differential lipid level analysis 
Differential lipid level analysis comparing FMD patients to healthy controls was 
performed using a linear regression for each parameter, using the reporter log2-
intensity as the outcome, a 0/1 indicator status for FMD, and the following additional 
covariates: age, BMI, use of statin (0/1), use of other lipid lowering medications (0/1). 
Significance of the association was quantified via t test on the FMD coefficient. FDR 
was quantified using the Benjamini-Hochberg procedure. 
To assess model robustness with respect to potential nonlinear effects of age on 
lipid levels, we additionally used a generalized additive model as implemented in the 
‘mgcv’ R software, version 1.8-24.2 In the generalized additive model, we replaced the 
linear term for age with a thin plate regression spline,3 leaving all other terms 
unchanged. Association between lipid levels and other clinical features was estimated 
within FMD patients with a linear regression, with the log2-transformed lipid levels as 
the outcome, and fixed covariates: age, BMI and cohort ID (when relevant). 
Associations with both FMD and other clinical features were estimated within the 
discovery cohort only, validation cohort only, and in the pooled dataset. 
 
Gene set enrichment analysis 
We performed Gene Set Enrichment Analysis (GSEA) on the differential protein level 
analysis results using the GSEA software from the Broad Institute and the MSigDB 
database,4 thus obtaining for each tested gene set both a significance of enrichment 
(nominal P value and permutation-based Q value) and a direction, quantified by the 
Normalized Enrichment Score (NES). We first mapped each probe to an entrez gene 
ID. Probes mapping to multiple entrez IDs were discarded; when multiple probes 
mapped to the same entrez ID, we kept the one with the smallest association P value. 
We then performed the enrichment analysis using the ‘ranks’ method, ranking the genes 
by their t statistic, and quantified the FDR separately for each gene set collection using 
1000 permutations. 
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Cross-correlations between proteins and lipids 
Cross-correlations between plasma protein and lipid levels were estimated separately 
within the discovery and validation cohorts using the Pearson correlation test. Results 
were then combined using a fixed effects meta-analysis, with inverse variance weights, 
using the ‘metacor’ function from the meta R package,5 using default options. 
 
Protein-quantitative trait locus (pQTL) mapping 
As described above, of the 190 subjects in the discovery cohort, 170 were of genotype-
confirmed Caucasian ancestry. To minimize background genetic heterogeneity, only 
these confirmed Caucasian subjects were used for pQTL studies. For each specific 
Olink probe we further eliminated subjects with missing data (certain Olink probes had a 
< 100% success rate), such that, ultimately, between 164 and 170 subjects entered the 
association analysis (depending on the Olink probe). 
A linear regression model was adopted to map pQTLs: y ~ 
EffectiveAlleleCopyNumber + Age + Disease Status, where 'y' is the inverse-normal 
transformed protein level, 'EffectiveAlleleCopyNumber' is the imputed allele copy 
number for a specific SNP, and ‘Disease Status’ is the indicator of the case/control 
status (1 for FMD cases, 0 for healthy controls). Significance of the genotype effect was 
quantified with a t test on its coefficient. Results were classified according to the genetic 
distance (in base-pairs) between the variant and the closest gene end. We classified as 
‘cis’ all variant-probe associations within 500kb, and as ‘trans’ all other associations. 
The distribution of the tests P values across all cis (trans) effects under the null 
hypothesis of no correlation between genotype and protein level was estimated by re-
running the analysis on a null dataset obtained by permuting the genotype subject 
identifiers. FDR was quantified by comparing the observed distribution of the test 
statistic with that estimated from the permuted data, as previously described.6-9 
 
Lipids genome wide association study (GWAS) 
Association between lipid levels and imputed genotypes was assessed within subjects 
of Caucasian ancestry by linear regression, with the log2-transformed lipid level as the 
outcome, and the imputed effective allele dosage as a regressor. Other covariates 
included in the model were age and FMD disease status (0/1). We studied enrichment 
for known HDL and LDL cholesterol loci in our results by comparing the distribution of 
the GWAS P values across the entire genome in our discovery cohort and that of loci 
previously published in Willer et al10 with a P value < 10-5. 
 
Bayesian network analysis 
We performed a Bayesian network analysis of the relationship between genetically 
controlled protein levels (i.e. proteins with a pQTL(s)) and FMD disease status using the 
‘deal’ R package11 and adapting a strategy previously described in the context of 
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experimental data.12 Specifically, a separate analysis was run for each gene variant-
protein combination. For each gene variant-protein pair, an analysis was conducted 
including the following variables: ‘variant’ (discrete: AA, AB or BB), ‘protein 
concentration’ (continuous), and ‘FMD’ (binary: 0/1). For each protein, there were 2 
possible relationships (links) between the gene variant and the abundance of this 
protein (no link or a link directed from genotype to protein level but not vice-versa), and 
there were 3 possible links between FMD and the abundance of this protein (no link, a 
link directed from the protein to FMD, and a link directed from FMD to the protein), 
resulting in a total of 12 possible networks (3 possible networks between a protein and 
FMD × 2 possible networks between the protein and the gene variant × 2 possible 
networks between FMD and the gene variant). Based on this, for each gene variant-
protein pair we estimated 12 possible networks and ranked them according to their 
score. Then, we categorized each protein according to its relationship with FMD based 
on the following criteria: 1) if the relative score of the second best network compared to 
the first was above 0.9, a protein was classified as “ambiguous”; 2) if the top network 
showed an outgoing edge from a protein to FMD, the protein was classified as 
“upstream”; 3) if the top network showed an outgoing edge from FMD to the protein, the 
protein was classified as “downstream”; 4) if none of the above 3 conditions were met, a 
protein was classified as “independent” (with regard to FMD). As for each protein, 
multiple variants were tested and results were further summarized at the protein level 
with a consensus category across all tested variants. If all variants did not lead to the 
same classification, the protein was classified as ‘indeterminate’. 
 
Association of pQTL genes with FMD genetic risk  
We performed a direct query for association with FMD of the genes that encode the five 
FMD signature proteins that also have an associated pQTL (CD2AP, PODXL2, TACC3, 
INPPL1, CRTAC1). Look-up for association with FMD was conducted in a French case-
control study including 506 FMD patients, and 876 controls ascertained from the 3C 
study as described previously.13 Clinical details for FMD patients have previously been 
described.14 Consistent with the current study and also prior analyses of this French 
case-control study,14 the query was performed only on females. Genotypes were 
generated using Illumina-OmniExpress-Exome in FMD cases, and Illumina-660-Quad 
array in the controls. Imputation of SNPs was performed using the HRC r1.1 2016 
reference panel15 separately in the two cohorts using MACH algorithm supported by the 
Michigan Imputation Server (https://imputationserver.sph.umich.edu/index.html). We 
applied standard quality control filters as recommended,16 primarily being individual’s 
call rate < 97%, extreme heterozygosity, sex-discordant, duplicate or relatedness, 
deviation from Hardy-Weinberg Equilibrium in cases and/or controls (P < 10−5) and 
minor allele frequency (MAF) < 0.01. All participants studied were genetically 
determined as Europeans using the EIGENSTRAT program17 and visualized by 
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principal components analysis (PCA) including 1000 genomes samples. Quality control 
was conducted using PLINK (version 1.07)18 and with adjusted association analyses by 
SNPTEST.19 In addition to age, we included the first five principal components axes as 
covariates to control for hidden population stratification. Association was visualized at 
the CD2AP locus using LocusZoom v0.4.8.20 
 
Immune-fluorescence staining for CD2AP 
Immune-fluorescence staining was performed using non-FMD adult human arterial 
samples obtained under a separate study protocol that was approved by the institutional 
review board of the Icahn School of Medicine at Mount Sinai. Full details of this protocol 
and our immune-fluorescence staining methods have previously been published.21 In 
brief, for immune-fluorescence staining of frozen sections embedded in OCT, thawed 
slides were washed and fixed with 4% paraformaldehyde in PBS for 10 minutes at room 
temperature. Slides were then washed and blocked with 10% heat-inactivated fetal 
bovine serum in PBS with 0.1% Triton-100. Diluted primary antibodies were applied and 
incubated overnight at 4°C as follows: anti-CD2AP (ab84829; Abcam, Cambridge, UK; 
1:100), anti-CD31 (ab9498; Abcam; 1:100). Slides were then washed and diluted 
donkey Alexa fluor 488 and 546 secondary antibodies were applied and incubated for 
30 minutes at room temperature (a21202 and a10040 respectively, Invitrogen, 
Carlsbad, CA; 1:200). Slides were then washed again and DAPI-containing mounting 
medium was applied (Vector Laboratories, Burlingame, CA). Slides were imaged using 
an inverted confocal microscope (SP5 DMI, Leica, Wetzlar, Germany).  
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Supplemental Figures 
 
 
Figure S1. Effects of age on plasma lipids in FMD cases versus matched controls 
(A) Beta values and (B) Z scores from FMD signature models including age as a linear 
term on the horizontal axis, versus age as a non-linear term on the vertical axis 
(smoothing spline, see Methods). These differing models for age showed no impact on 
the plasma lipid signature for FMD.   
12 
 
 
Figure S2. Validation of lipid data - Enrichment for known LDL and HDL loci in 
discovery cohort lipid GWAS 
We sought to validate the robustness of our lipid and genotype data by comparing 
genetic association statistics from our discovery cohort with previously published HDL 
and LDL cholesterol GWAS results from a larger cohort.10 We found that our results 
were positively enriched for loci associated with HDL and LDL, respectively, validating 
the reliability of our measurements. Shown here are Q-q plots of enrichment for known 
HDL and LDL loci in the discovery cohort, showing log10(P value) of genotype 
association with lipid levels across the entire genome (horizontal axis) vs known loci 
(vertical axis). Known lipid loci were defined as loci with P value < 1.0 x 10-5 from Willer 
et al.10 
 
 
13 
 
Figure S3. Plasma endothelin-1 (EDN1) levels in FMD subjects versus matched 
controls, and in relation to genotype at rs9349379 
A recent report suggested that rs9349379 and FMD may be related to plasma protein 
levels of EDN1.22 Specifically, this report showed reduced levels of EDN1 with the A 
allele at rs9349379, leading to speculation that reduced levels of EDN1 may be 
14 
associated with FMD.22 The Olink high-throughput platform used in this study did not 
measure EDN1 levels, and we therefore undertook a separate quantitation of this 
protein by ELISA in the discovery cohort. (A) In unadjusted and BMI-adjusted analyses 
EDN1 levels were higher in FMD cases versus matched controls (P = 0.034 and P = 
0.033, respectively). The association became non-significant after adjustment for age (P 
= 0.153), and also after adjustment for both age and BMI as was applied to other 
protein/lipid data throughout this study (P = 0.150). (B) In a pooled analysis of all 
subjects in the discovery cohort with adjustment for disease status, there was also no 
relationship between EDN1 levels and genotype at rs9349379 either in a model that had 
no further adjustment, or with adjustment for age and BMI. Because disease status 
influenced EDN1 levels, we further analyzed the relationship between EDN1 levels and 
genotype at rs9349379 with separate analyses for cases and controls. While there was 
a trend to reduced levels of EDN1 among FMD cases with the A allele at rs9349379, 
both in an unadjusted analysis and after adjusting for age and BMI, this did not reach 
statistical significance. (C) Reanalysis of (B) using an inverse normal transformation 
method gave similar results. Results in (C) are adjusted for age only. 
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Figure S4. GWAS for EDN1 levels 
To demonstrate the validity of our data for EDN1, we explored potential pQTLs 
associated with this protein. No genome-wide significant loci were found for EDN1. (A) 
q-q plot. (B) Manhattan plot. (C) Locus zoom plot showing that rs12192252 is a 
suggestive pQTL for EDN1 (P = 6.7x10-6), which lies 110kb upstream from the coding 
region for EDN1. 
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Supplemental Tables 
 
Table S1. Differential protein analysis comparing FMD patients to matched 
healthy controls (included in a separate Excel file) 
This analysis was performed with statistical correction for age and body mass index 
(BMI). At 10% FDR, we identified 105 proteins (104 distinct gene symbols) differentially 
abundant in the plasma of FMD cases compared to controls. Included here are data 
from the discovery cohort, validation cohort and the pooled results of both cohorts. BH, 
Benjamini-Hochberg corrected. 
 
Table S2. Gene Set Enrichment Analysis (GSEA) of the FMD protein signature 
against the MSigDB database (included in a separate Excel file) 
For each tested gene set we obtained both a significance of enrichment (nominal P 
value and permutation-based Q value) and a direction, quantified by the Normalized 
Enrichment Score (NES). A positive NES indicates upregulation of the proteins in the 
genes set within FMD patients when compared to healthy controls (and vice-versa). ES, 
Enrichment Score; FWER, Family-Wise Error Rate; NOM, nominal. 
 
Table S3. Impact of medications on FMD signature proteins: z scores (included in 
a separate Excel file) 
Z-scores of protein associations with FMD disease status (all subjects) and differing 
classes of medication use (estimated within FMD patients only), for all FMD signature 
proteins identified in the discovery cohort. These z-scores are displayed as a heatmap 
in Figure 2. 
 
Table S4. Regression model examining the effect of medication use on the FMD 
plasma protein signature (included in a separate Excel file) 
FMD regression model in which we sequentially excluded both cases and controls 
according to the use of differing classes of medications. The resulting perturbed FMD 
protein lists consistently, and strongly, overlapped with our full FMD protein signature 
obtained by including all subjects. 
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Table S5. FMD signature proteins (from the discovery analysis) that are 
associated with plasma lipid levels.  
Protein 
symbol 
Full protein 
name 
Lipid Association References 
ANGPTL3 Angiopoietin-like 
3 
Regulates lipid levels by affecting 
lipoprotein lipase- and endothelial 
lipase-mediated hydrolysis of 
triglycerides and phospholipids. 
See review by Tikka 
and Jauhiainen 23 
C1QTNF1 C1q/TNF-
related protein 1 
Regulates systemic energy 
metabolism including lipids. 
Rodriguez et al 24 
DAB2 Disabled-2 DAB2 is a low density lipoprotein 
receptor (LDLR) endocytic 
adaptor protein that controls 
cholesterol homeostasis. 
Tao et al 25 
DLL1 Delta-like 1 Animal studies have shown 
reduced DLL1 leads to reduced 
cholesterol and triglyceride levels 
in blood. 
Rubio-Aliaga et al 26 
DPP4 Dipeptidyl 
peptidase-4 
DPP4 inhibitors downregulate 
hepatic lipid synthesis. 
Monami et al 27; 
Yano et al 28 
 
FABP4 Fatty acid 
binding Protein 
4 
Regulates fatty acids and 
systemic energy metabolism. 
Syamsunarno et al 29; 
Gan et al 30 
FADD Fas-associated 
protein with 
death domain 
Shown to be a key regulator of 
lipid metabolism. 
Zhuang et al 31 
FGF19 Fibroblast 
growth factor 19 
Regulates skeletal muscle mass, 
energy expenditure, and lipid and 
glucose homeostasis. 
Wu et 32; 
Benoit et al 33 
 
FGF21 Fibroblast 
growth factor 21 
FGF21 lowers plasma 
triglycerides by accelerating 
lipoprotein catabolism. Elevation 
of plasma FGF21 levels reduces 
body weight, decreases 
hyperglycemia and 
hyperlipidemia, and increases 
insulin sensitivity. 
Schlein et al 34; 
Xu et al 35 
 
 
 
GCG Glucagon A master regulator of glucose and 
lipid metabolism, that includes 
effects on lipolysis, energy 
balance, adipose tissue mass and 
food intake. 
See review by 
Habegger et al 36 
 
LPL Lipoprotein 
lipase 
Has the dual functions of 
triglyceride hydrolase and 
ligand/bridging factor for receptor-
See review by He et al 
37 
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mediated lipoprotein uptake. 
METAP2 Methionine 
aminopeptidase 
2  
In a randomized, double-blind, 
placebo-controlled trial in patients 
with Prader-Willi syndrome, 
METAP2 inhibition led to 
improvements in hyperphagia-
related behaviors, and reduced 
total cholesterol and LDL 
cholesterol levels. 
McCandless et al 38 
PDRX6 Peroxiredoxin 6 In animal models knockout of 
PRDX6 is associated with 
increased VLDL and triglyceride 
levels, and reduced HDL 
cholesterol levels. 
Pacifici et al 39 
PROC Protein C Genetic variants have been 
identified linking PROC to 
lipoprotein metabolism. 
Pankow et al 40 
PRSS8 Prostasin PRSS8 is involved in protecting 
against insulin resistance. High fat 
diet feeding in mice 
downregulates PRSS8 in the liver, 
contributing to the development of 
hepatic insulin resistance and 
diabetes. 
Uchimura et al 41 
SERPINA12 SERPIN A2; 
also known as 
VASPIN 
(visceral 
adipose tissue-
derived serpin) 
Higher VASPIN serum 
concentrations and gene 
expression in human adipose 
tissue are associated with obesity, 
insulin resistance, and type 2 
diabetes in humans. 
Yang et al 42; Review 
by Blüher 43 
SEZ6L Seizure Related 
6 Homolog Like 
Potentially plays a role in 
cholesterol and LDL cholesterol 
handling at the cellular level. 
Blattmann et al 44 
TIMD4 T-cell 
immunoglobulin 
and mucin 
domain 4 
Genetic variants associated with 
TIMD4 have been associated with 
lipid levels in Chinese 
populations.  
Zhang et al 45; Zhang 
et al 46 
 
vWF von Willebrand 
factor 
Plasma vWF levels have been 
shown to be higher in patients 
with the metabolic syndrome.          
Lim et al 47 
ZBTB16 Zinc finger and 
BTB domain 
containing 16 
ZBTB16 has a role in brown 
adipocyte bioenergetics and gene 
variants associated with ZBTB16 
influence obesity-related 
parameters and lipid levels. 
Plaisier et al 48; 
Bendlova et al 49 
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Table S6. Differential lipid analysis comparing FMD patients to matched healthy 
controls, with a fully adjusted model (included in a separate Excel file) 
This fully adjusted model included the co-variates of age, BMI, statin use and non-statin 
lipid lowering medication use. BH, Benjamini-Hochberg corrected; NGID, Nightingale 
identification code.  
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Table S7. Validation cohort demographic summary statistics 
 
  FMD patients (n=23) healthy controls (n=28) 
 variable summary* n summary* n
Clinical     
 Sex: female 23 (100.00%) 23 28 (100.00%) 28
 Age at diagnosis 53 [32 – 73] -
 Age at enrollment 55 [32 - 80] 23 52 [33 - 81] 28
 Height (in) 65.0 [59.0 - 69.5] 23 65.0 [59.0 - 69.0] 28
 Weight (lbs) 137.0 [113.0 - 248.0] 23 137.5 [115.0 - 190.0] 28
 BMI 23.6 [20.3 - 40.1] 23 23.2 [18.2 - 32.2] 28
 DM 0 (0.0%) 23 1 (3.57%) 28
 HTN 12 (52.17%) 23 1 (3.57%) 28
 Ever smoker  9 (39.13%) 23 3 (10.71%) 28
Medication use   
 ACE/ARB 10 (43.48%) 23 0 (0.0%) 28
 Aspirin 21 (91.30%) 23 0 (0.0%) 28
 Anticoagulation 2 (8.70%) 23 0 (0.0%) 28
 Beta Blocker 7 (30.43%) 23 1 (3.57%) 28
 Current hormone therapy 3 (13.04%) 23 6 (21.43%) 28
 Statin 7 (30.43%) 23 2 (7.14%) 28
 Non-statin lipid lowering 
Thyroid replacement 
0 (0.0%) 
6 (26.09%)
23 
23
1 (3.57%) 
6 (21.43%)
28 
28
FMD vascular features   
 Aneurysm 7 (30.43%) 23 - 
 Dissection 10 (43.48%) 23 - 
 TIA/CVA 4 (17.39%) 23 - 
FMD arterial disease location    
 Cervical (Carotid/Vertebral) 23 (100.00%) 23  - 
 Coronary# 4 (17.39%) 23  - 
 Iliac 8 (34.78%) 23  - 
 Intracranial# 4 (17.39%) 23  - 
 Mesenteric 7 (30.43%) 23  - 
 Renal 12 (52.17%) 23  - 
FMD arterial bed involvement    
 Total number of arterial 
beds involved 
2.0 [1.0 - 5.0] 23  - 
* Total number of subjects with the described characteristic for yes/no features 
(percentage in parenthesis); median and min-max range for continuous features. ACE = 
angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; BMI = 
body mass index; DM = diabetes; HTN = hypertension; statin = HMG-CoA reductase 
inhibitor; TIA = transient ischemic attack; CVA = cerebrovascular accident 
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Table S8. Associations between plasma protein levels and FMD disease features 
and severity (included in a separate Excel file) 
There were no significant associations between plasma protein levels and FMD disease 
features. BH, Benjamini-Hochberg corrected. 
 
Table S9. Associations between plasma lipid levels and FMD disease features and 
severity (included in a separate Excel file) 
There were no significant associations between plasma protein levels and FMD disease 
features. BH, Benjamini-Hochberg corrected; NGID, Nightingale identification code.  
 
Table S10. Protein quantitative trait loci mapping on Caucasian FMD patients and 
healthy control subjects (included in a separate Excel file) 
At 10% FDR, we found 193 cis, and 34 trans pQTLs, for a total of 219 distinct probes. 
 
Table S11. Protein quantitative trait loci at rs9349379 (included in a separate 
Excel file) 
At a FDR of 10%, there were no plasma protein parameters associated with genotype at 
rs9349379. 
 
Table S12. Lipid quantitative trait loci at rs9349379 (included in a separate Excel 
file) 
At a FDR of 10%, there were no plasma lipid parameters associated with genotype at 
rs9349379. NGID, Nightingale identification code.  
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